

PRELIMINARY PROGRAM

BEST OF ASCO®

OFFICIALLY LICENSED

August 29 - 30, 2024,
Almaty, Kazakhstan

30/08/2024 - DAY 2	
Prevention, Risk Reduction and Hereditary Breast Cancer Chairs: Aliya Abdrakhmanova/Irakli Kokhreidze	10:00 - 11:00
Nia Sharikadze Professor, Head of Clinical Oncology Department of Mardaleishvili Medical Center Georgia Baseline characteristics (BL) and efficacy endpoints for patients with node-negative (N0) HR+/HER-early breast cancer (EBC):NATALEE	10:00 - 10:30
Nazgul Omarbayeva PhD candidate, oncologist-mammologist of Breast Tumor Center KazIOR Kazakhstan Clinical behavior of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing: Results from an international cohort study	10:30 - 10:50
Discussion	10:50 - 11:00
Breast Cancer—Metastatic Chairs: Aliya Abdrakhmanova/Irakli Kokhreidze	11:00 - 11:40
Irakli Kokhreidze MD, PhD, Professor, expert of the Ministry of Health, Labor and Social Protection of Georgia, Head of the oncology department of the Caraps Medline clinic, Chief mammologist of the Evex clinic Network Georgia TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2	11:00 - 11:30
Discussion	11:30 - 11:40
Coffee break	11:40 - 12:00
Gynecologic Cancer Chairs: Dilyara Kaidarova/Zaza Tsitsishvili	12:00 - 13:10
Maia Dzhugashvili PhD, Professor, Radiation oncologist of “GenesisCare” Madrid, Spain	12:00 - 12:30

Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy: Results of NRG oncology/RTOG 0724/GOG-0724	
Don S. Dizon MD, Director of Pelvic Malignancies Program and Hematology- Oncology Outpatient Clinics, Director of Medical Oncology of Rhode Island Hospital, Founder of the USA Cancer Sexual Health Emergency Response Program USA Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial	12:30 - 13:00
Discussion	13:00 - 13:10
Lunch	13:10 - 14:00